Tapering Order in Sustained Remission: Biologic First or Methotrexate First
Sustained remission earns a taper, but which drug comes down first depends on facts about her liver and kidneys that the usual sequencing doesn't take into account.
Elena V., a 71-year-old woman, has kept a large plot at her town's community garden since her husband passed six years ago, and the two hours she spends there most mornings, she says, are the one part of her day that hasn't changed since. Her rheumatoid arthritis, eight years old, has been in sustained DAS28 remission for fourteen months on etanercept combined with methotrexate at 15mg weekly, and today's visit is the one her rheumatologist has been planning toward: whether, and how, to start tapering.
Two findings complicate what would otherwise be a straightforward biologic-first taper, the more commonly practiced sequence since maintaining methotrexate alongside a biologic is known to reduce anti-drug antibody formation and support a cleaner restart if the biologic is needed again later. Her ALT has run at 1.5 times the upper limit of normal for the past year, stable and judged tolerable by her hepatologist, but not zero; and her eGFR has drifted down to 52 over the same period from a baseline near 70, age-related decline that reduces her kidney's ability to clear a renally-cleared drug like methotrexate even at an unchanged dose — the same weekly prescription that once cleared briskly now sits in her system measurably longer between doses. EULAR's 2025 update reinforces that sustained remission supports reducing DMARD dose or frequency, not stopping either drug outright — most patients who fully discontinue a DMARD in remission flare within a year, evidence the task force specifically strengthened in this update — but the guideline doesn't specify which drug should come down first when, as here, one of the two carries its own quietly accumulating signal rather than both aging at the same rate.
Which drug comes down first
I'd taper the etanercept first and keep her methotrexate steady. Methotrexate co-therapy is known to reduce anti-drug antibody formation, so if we ever need to restart the biologic later, keeping her on it now protects that option. That's the sequence most patients in sustained remission follow.
I'd flip the order for her specifically. Her ALT has sat at one and a half times normal for a year, and her eGFR has dropped from around 70 to 52 over the same stretch — methotrexate is renally cleared, so a declining eGFR means the same unchanged dose is effectively a slowly rising exposure, not a stable one.
The antibody-formation argument for keeping methotrexate steady is real, but it's a general population default, not a fact about her specifically — and EULAR's own 2025 update explicitly supports reducing dose rather than holding either drug fixed once remission is sustained. I'd rather address the signal we already have in front of us than protect an antibody-formation advantage for a biologic restart that may never be needed.
I'd concede that tapering the biologic first is the better-trodden path and I'm not saying it's wrong in general — just that her own labs are a specific enough reason to make an exception here.
Agreed: methotrexate reduced from 15mg to 10mg weekly first, with etanercept unchanged, and transaminases and renal function rechecked in six weeks before deciding the next step.
Not agreed: whether this sequence should become her general practice going forward, or whether it's a one-time exception justified by her specific labs. The rheumatologist's view is that the antibody-formation rationale for biologic-first tapering remains sound as a general default; the pharmacologist's view is that her numbers were specific enough to warrant reversing it here, without either voice generalizing the exception into a new rule.